Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call Transcript May 13, 2024 5:00 PM ET Company Participants Rick Winningham – Chief Executive OfficerAine Miller – Head, DevelopmentRhonda Farnum – Chief Business OfficerAziz Sawaf – Chief Financial Officer Conference Call Participants Douglas Tsao – H.C. WainwrightJulian Harrison – BTIGDavid Risinger – Leerink PartnersMarc Frahm – TD…
alengo It’s been a little while since I’ve published a portfolio review, but in recent months, I’ve continued to take strides reshaping my portfolio into my desired long-term form, so I wanted to take some time this week to provide an update for everyone. In short, I’ve been intensely focused on accumulating shares of blue…
YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Conference Call April 19, 2024 8:00 AM ET Company Participants Alyssa Li – Director, Investor RelationsDavid Shao – President & Chief Executive OfficerZenaida Mojares – Chief Medical OfficerBrenda Wu – Chief Financial Officer Conference Call Participants Hunter Diamond – Diamond Equity Research Operator Ladies and gentlemen, thank…
M-image/iStock via Getty Images It has been over a year since my last Xeris Biopharma (NASDAQ:XERS) article, where I reviewed the company’s 2022 achievements including record net product revenue, driven by robust growth in our approved product portfolio. In addition, I also pointed out that company management was confident in their trajectory toward cash flow…
ALIOUI Mohammed Elamine/iStock via Getty Images Deals and Financings ArriVent BioPharma (AVBP), a Philadelphia in-licensing company, priced its upsized NASDAQ IPO at $18 per share, raising $175 million (see story). The company’s stated goal is to find promising novel assets from China and other countries, which it brings to the US market. ArriVent’s lead product…
Love Employee/iStock via Getty Images Xeris Biopharma Holdings (NASDAQ:XERS) is up 88% (YoY) and the stock price is trading just 23.5% shy of the 52-week high of $3.07. It has been four years since the U.S. FDA approved Gvoke, the prefilled (ready-to-use) glucagon drug for the treatment of hypoglycemia in diabetes patients (from 2 years…
Love Employee/iStock via Getty Images Topline Summary Immix Biopharma (NASDAQ:IMMX) is a biotech company focused on development of novel CAR-T and other cell-based therapies for cancers and heme disorders. They are joining a growing group of companies using natural killer cell-based immunotherapy, which remains promising but unproven. Still, IMMX has a bit more data than…
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) UBS Biopharma Conference November 9, 2023 12:00 PM ET Company Participants Charlie Wagner – Executive Vice President & Chief Financial Officer David Altshuler – Chief Scientific Officer Conference Call Participants Colin Bristow – UBS Colin Bristow Good afternoon, and welcome to the UBS Biopharma Conference. I’m Colin Bristow, one of the…
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET Company Participants Ryan Crowe – Vice President, Investor Relations Brook Jennings – Vice President, Immunology Marketing Conference Call Participants Colin Bristow – UBS Colin Bristow Well, good morning, and welcome to the UBS Biopharma Conference. I am Colin Bristow, one of…
piola666 I called out the near-term risk of China’s deterioration for Mettler-Toledo (NYSE:MTD) in my introductory article back in September. Mettler-Toledo posted a very weak Q3 FY23 result on November 9th, with a -5% decrease in revenue on a constant currency basis and a -3.7% decline in adjusted EPS year over year. I believe the…
Kitsawet Saethao/iStock via Getty Images Ambrx Biopharma Inc. (NASDAQ:AMAM) has made great progress in advancing its pipeline towards several types of cancer therapeutics. One such drug would be the use of ARX517, which is an anti-PSMA antibody drug conjugate [ADC], which is being developed for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC]….
Dr_Microbe/iStock via Getty Images Analysis is the art of creation through destruction.”― P.S. Baber It has been a bit over a year since we had Arbutus Biopharma Corporation (NASDAQ:ABUS) in the spotlight here at The Biotech Forum. We concluded that article by saying the stock merited a small, covered call holding as liquidity was good…
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum – IR Josh Disbrow – CEO Mark Oki – CFO Conference Call Participants Naz Rahman – Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call. At this time, all participants…
Pfizer Inc. (NYSE:PFE) Citi’s 18th Annual BioPharma Conference September 7, 2023 10:30 AM ET Company Participants Mikael Dolsten – Chief Scientific Officer & President, Pfizer Research & Development Christopher Stevo – SVP & Chief IR Officer Conference Call Participants Andrew Baum – Citi Andrew Baum So delighted to introduce Mikael Dolsten. Mikael is President R&D,…
Merck & Co., Inc. (NYSE:MRK) Citi 18th Annual BioPharma Conference September 6, 2023 1:50 PM ET Company Participants Marjorie Green – SVP and Head of Late Stage Oncology, Global Clinical Development Conference Call Participants Andrew Baum – Citi Andrew Baum So delighted to introduce our next speaker, Dr. Marjorie Green at Merck, who heads Oncology…
LaylaBird A Quick Take On RayzeBio, Inc. RayzeBio, Inc. (RYZB) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement. The firm is a clinical-stage biopharma developing radiopharmaceutical treatments for cancer conditions. RYZB has extensive resources to fund its development programs and is backed by…
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Allison Wey – Senior Vice President of Investor Relations Paul Edick – Chairman and Chief Executive Officer Steven Pieper – Chief Financial Officer Conference Call Participants Oren Livnat – H. C. Wainwright Glen Santangelo – Jefferies Operator…